Prognostic and predictive biomarkers in colorectal cancer. From the preclinical setting to clinical practice

Current Cancer Drug Targets

Volumn 15, Issue 8, 2015, Pages 703-715

  Maurel, Joan ^a,b,c   Postigo, Antonio ^b,c,d,e  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Biomarkers; Colorectal; Epithelial; Mesenchymal; Prognostic; Resistance

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; ERLOTINIB; NIVOLUMAB; PANITUMUMAB; PERFORIN; RAMUCIRUMAB; TRASTUZUMAB; VEMURAFENIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE MUTATION; GENOTYPE; HUMAN; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; PHENOTYPE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; COLORECTAL NEOPLASMS; DRUG RESISTANCE; METABOLISM; PREDICTIVE VALUE; PROGNOSIS; TRANSLATIONAL RESEARCH;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84945931314     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800961508151001102822     Document Type: Article

References (160)

1. Smith, C,G.; Fisher, D.; Claes, B.; Maughan, T.S.; Idziaszczyk, S.; Peuteman, G.; Harris, R.; James, M.D.; Meade, A.; Jasani, B.; Adams, R.A.; Kenny, S.; Kaplan, R.; Lambrechts, D.; Cheadle, J.P. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin. Cancer Res., 2013, 19, 4104-4113.
2. Molinari, F.; Felicioni, L.; Buscarino, M.; De Dosso, S.; Buttitta, F.; Malatesta, S.; Movilia, A.; Luoni, M.; Boldorini, R.; Alabiso, O.; Girlando, S.; Soini, B.; Spitale, A.; Di Nicolantonio, F.; Saletti, P.; Crippa, S.; Mazzucchelli, L.; Marchetti, A.; Bardelli, A.; Frattini, M. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin. Cancer Res., 2011, 17, 4901-4914.
3. Peeters, M.; Oliner, K.S.; Parker, A.; Siena, S.; Van Cutsem, E.; Huang, J.; Humblet, Y.; Van Laethem, J.L.; Andre, T.; Wiezorek, J.; Reese, D.; Patterson, S.D. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin. Cancer Res., 2013, 19, 1902-1912.
4. Ciardiello, F.; Normanno, N.; Maiello, E.; Martinelli, E.; Troiani, T.; Pisconti, S.; Giuliani, F.; Barone, C.; Carteni, G.; Rachiglio, A.M.; Montesarchio, V.; Tonini, G.; Rizzi, D.; Cinieri, S.; Bordonaro, R.; Febbraro, A.; De Vita, F.; Orditura, M.; Fenizia, F.; Lambiase, M.; Rinaldi, A.; Tatangelo, F.; Botti, G.; Colucci, G. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ann. Oncol., 2014, 25, 1756-1761.
5. Maughan, T.S.; Adams, R.A.; Smith, C.G.; Meade, A.M.; Seymour, M.T.; Wilson, R.H.; Idziaszczyk, S.; Harris, R.; Fisher, D.; Kenny, S.L.; Kay, E.; Mitchell, J.K.; Madi, A.; Jasani, B.; James, M.D.; Bridgewater, J.; Kennedy, M.J.; Claes, B.; Lambrechts, D.; Kaplan, R.; Cheadle, J.P. MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet, 2011, 377, 2103-2114.
6. Van Cutsem, E.; Kohne, C.H.; Lang, I.; Folprecht, G.; Nowacki, M.P.; Cascinu, S.; Shchepotin, I.; Maurel, J.; Cunningham, D.; Tejpar, S.; Schlichting, M.; Zubel, A.; Celik, I.; Rougier, P.; Ciardiello, F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol., 2011, 29, 2011-2019
7. Douillard, J.Y.; Siena, S.; Cassidy, J.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; Rivera, F.; Kocakova, I.; Ruff, P.; Błasińska-Morawiec, M.; Šmakal, M.; Canon, J.L.; Rother, M.; Oliner, K.S.; Wolf, M.; Gansert, J. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. J. Clin. Oncol., 2010, 28, 4697-4705.
8. Peeters, M.; Price, T.J.; Cervantes, A.; Sobrero, A.F.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.J.; Strickland, A.H.; Wilson, G.; Ciuleanu, T.E.; Roman, L.; Van Cutsem, E.; Tzekova, V.; Collins, S.; Oliner, K.S.; Rong, A.; Gansert, J. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol., 2010, 28, 4706-4713.
9. Seymour, M.; Brown, S.R.; Middleton, G.; Maughan, T.; Richman, S.; Gwyther, S.; Lowe, C.; Seligmann, J.F.; Wadsley, J.; Maisey, N.; Chau, I.; Hill, M.; Dawson, L.; Falk, S.; O'Callaghan, A.; Benstead, K.; Chambers, P.; Oliver, A.; Marshall, H.; Napp, V.; Quirke, P. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol., 2013, 14, 749-759.
10. Karapetis, C.S.; Khambata-Ford, S.; Jonker, D.J.; O'Callaghan, C.J.; Tu, D.; Tebbutt, N.C.; Simes, R.J.; Chalchal, H.; Shapiro, J.D.; Robitaille, S.; Price, T.J.; Shepherd, L.; Au, H.J.; Langer, C.; Moore, M.J.; Zalcberg, J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med., 2008, 359, 1757-1765.
11. Amado, R.G.; Wolf, M.; Peeters, M.; Van Cutsem, E.; Siena, S.; Freeman, D.J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R.; Patterson, S.D.; Chang, D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol., 2008, 26, 1626-1634.
12. Douillard, J.Y.; Oliner, K.S.; Siena, S.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; Rivera, F.; Kocakova, I.; Ruff, P.; Błasińska-Morawiec, M.; Šmakal, M.; Canon, J.L.; Rother, M.; Williams, R.; Rong, A.; Wiezorek, J.; Sidhu, R.; Patterson, S.D. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med., 2013, 369, 1023-1034
13. Sanchez-Tillo, E.; Liu, Y.; de Barrios, O.; Siles, L.; Fanlo, L.; Cuatrecasas, M.; Darling, D.S.; Dean, D.C.; Castells, A.; Postigo, A. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol. Life Sci., 2012, 69, 3429-3456
14. De Craene, B.; Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer, 2013, 13, 97- 110
15. Puisieux, A.; Brabletz, T.; Caramel, J. Oncogenic roles of EMTinducing transcription factors. Nat. Cell Biol., 2014, 16, 488-494
16. Arumugam, T.; Ramachandran, V.; Fournier, K.F.; Wang, H.; Marquis, L.; Abbruzzese, J.L.; Gallick, G.E.; Logsdon, C.D.; McConkey, D.J.; Choi, W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res., 2009, 69, 5820-5828
17. Wang, Z.; Li, Y.; Kong, D.; Banerjee, S.; Ahmad, A.; Azmi, A.S.; Ali, S.; Abbruzzese, J.L.; Gallick, G.E.; Sarkar, F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabineresistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res., 2009, 69, 2400-2407.
18. Wellner, U.; Schubert, J.; Burk, U.C.; Schmalhofer, O.; Zhu, F.; Sonntag, A.; Waldvogel, B.; Vannier, C.; Darling, D.; zur Hausen, A.; Brunton, V.G.; Morton, J.; Sansom, O.; Schuler, J.; Stemmler, M.P.; Herzberger, C.; Hopt, U.; Keck, T.; Brabletz, S.; Brabletz, T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol., 2009, 11, 1487- 1495
19. Zhang, J.; Tian XJ, Zhang H, Teng Y, Li R, Bai F, Elankumaran S, Xing J. TGF-β-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops. Sci Signal., 2014, 7(345), ra91
20. Pylayeva-Gupta, Yuliya, Elda Grabocka, and Dafna Bar-Sagi. "RAS oncogenes: weaving a tumorigenic web." Nature Reviews Cancer., 2011, 11 (11), 761-774.
21. Krauthammer, M.; Kong, Y.; Ha, B.H.; Evans, P.; Bacchiocchi, A.; McCusker, J.P.; Cheng, E.; Davis, M.J.; Goh, G.; Choi, M.; Ariyan, S.; Narayan, D.; Dutton-Regester, K.; Capatana, A.; Holman, E.C.; Bosenberg, M.; Sznol, M.; Kluger, H.M.; Brash, D.E.; Stern, D.F.; Materin, M.A.; Lo, R.S.; Mane, S.; Ma, S.; Kidd, K.K.; Hayward, N.K.; Lifton, R.P.; Schlessinger, J.; Boggon, T.J.; Halaban, R. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet., 2012, 44, 1006-1014.
22. Lambert, J.M.; Lambert, Q.T.; Reuther, G.W.; Malliri, A.; Siderovski, D.P.; Sondek, J.; Collard, J.G.; Der CJ. Tiam1 mediates Ras activation of Rac by a PI (3) K-independent mechanism. Nat. Cell Biol., 2002, 4, 621-625.
23. Gulhati, P.; Bowen, K.A.; Liu, J.; Stevens, P.D.; Rychahou, P.G.; Chen, M.; Lee, E.Y.; Weiss, H.L.; O'Connor, K.L.; Gao, T.; Evers, B.M. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res., 2011, 71, 3246-3256
24. Esufali, S.; Bapat, B. Cross-talk between Rac1 GTPase and dysregulated Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-mediated transcriptional activation. Oncogene, 2004, 23, 8260-8271.
25. Wu, X.; Tu, X.; Joeng, K.S.; Hilton, M.J.; Williams, D.A.; Long, F. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell, 2008, 133, 340-353.
26. Janssen, K.P.; Alberici, P.; Fsihi, H.; Gaspar, C.; Breukel, C.; Franken, P.; Rosty, C.; Abal, M.; El Marjou, F.; Smits, R.; Louvard, D.; Fodde, R.; Robine, S. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology. 2006, 131, 1096-1109.
27. Phelps, R.A.; Chidester, S.; Dehghanizadeh, S.; Phelps, J.; Sandoval, I.T.; Rai, K.; Broadbent, T.; Sarkar, S.; Burt, R.W.; Jones, D.A. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell, 2009, 137, 623-634
28. Simon, A.R.; Vikis, H.G.; Stewart, S.; Fanburg, B.L.; Cochran, B.H.; Guan, K.L. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science, 2000, 290, 144-147
29. Arulanandam, R.; Geletu, M.; Feracci, H.; Raptis, L. Activated Rac1 requires gp130 for Stat3 activation, cell proliferation and migration. Exp. Cell Res., 2010, 316, 875-886
30. Xiong, H.; Hong, J.; Du, W.; Lin, Y.W.; Ren, L.L.; Wang, Y.C.; Su, W.Y.; Wang, J.L.; Cui, Y.; Wang, Z.H.; Fang, J.Y. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J. Biol. Chem., 2012, 287, 5819-5832.
31. Myant, K.B.; Cammareri, P.; McGhee, E.J.; Ridgway, R.A.; Huels, D.J.; Cordero, J.B.; Schwitalla, S.; Kalna, G.; Ogg, E.L.; Athineos, D.; Timpson, P.; Vidal, M.; Murray, G.I.; Greten, F.R.; Anderson, K.I.; Sansom, O.J. ROS production and NF-κB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell, 2013, 12, 761-773.
32. Chua, H.L.; Bhat-Nakshatri, P.; Clare, S.E.; Morimiya, A.; Badve, S.; Nakshatri, H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene, 2007, 26, 11-24.
33. Jordan, P.; Brazao, R.; Boavida, M.G.; Gespach, C.; Chastre, E. Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene, 1999, 18, 6835-6839.
34. Matos, P.; Collard, J.G.; Jordan, P. Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling. J. Biol. Chem., 2003, 278, 50442-50448
35. Fiegen, D.; Haeusler, L.C.; Blumenstein, L.; Herbrand, U.; Dvorsky, R.; Vetter, I.R.; Ahmadian, M.R. Alternative splicing of Rac1 generates Rac1b, a self-activating GTPase. J. Biol. Chem., 2004, 279, 4743-4749.
36. Visvikis, O.; Lores, P.; Boyer, L.; Chardin, P.; Lemichez, E.; Gacon, G. Activated Rac1, but not the tumorigenic variant Rac1b, is ubiquitinated on Lys 147 through a JNK-regulated process. FEBS J., 2008, 275, 386-396.
37. Matos, P.; Jordan, P. Increased Rac1b expression sustains colorectal tumor cell survival. Mol. Cancer Res., 2008, 6, 1178-1184.
38. Radisky, D.C.; Levy, D.D.; Littlepage, L.E.; Liu, H.; Nelson, C.M.; Fata, J.E.; Leake, D.; Godden, E.L.; Albertson, D.G.; Nieto, M.A.; Werb, Z.; Bissell, M.J. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature, 2005, 436, 123-127
39. Matos, P.; Jordan, P. Rac1, but not Rac1B, stimulates RelBmediated gene transcription in colorectal cancer cells. J. Biol. Chem., 2006, 281, 13724-13732.
40. Esufali, S.; Charames, G.S.; Pethe, V.V.; Buongiorno, P.; Bapat, B. Activation of tumor-specific splice variant Rac1b by dishevelled promotes canonical Wnt signaling and decreased adhesion of colorectal cancer cells. Cancer Res., 2007, 67, 2469-2479
41. Pethe, V.V.; Charames, G.S.; Bapat, B. Rac1b recruits Dishevelled and β-catenin to Wnt target gene promoters independent of Wnt3A stimulation. Int. J. Oncol., 2011, 39, 805-810.
42. Goncalves, V.; Matos, P.; Jordan, P. Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Hum. Mol. Genet., 2009, 18, 3696-3707
43. Taube, J.H.; Herschkowitz, J.I.; Komurov, K.; Zhou, A.Y.; Gupta, S.; Yang, J.; Hartwell, K.; Onder, T.T.; Gupta, P.B.; Evans, K.W.; Hollier, B.G.; Ram, P.T.; Lander, E.S.; Rosen, J.M.; Weinberg, R.A.; Mani, S.A. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudinlow and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA., 2010, 107, 15449-15454.
44. Sanchez-Tillo, E.; de Barrios, O.; Siles, L.; Cuatrecasas, M.; Castells, A.; Postigo, A. β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc. Natl. Acad. Sci. USA., 2011, 108, 19204-19209
45. Wang, Y.; Bu, F.; Royer, C.; Serres, S.; Larkin, J.R.; Soto, M.S.; Sibson, N.R.; Salter, V.; Fritzsche, F.; Turnquist, C.; Koch, S.; Zak, J.; Zhong, S.; Wu, G.; Liang, A.; Olofsen, P.A.; Moch, H.; Hancock, D.C.; Downward, J.; Goldin, R.D.; Zhao, J.; Tong, X.; Guo, Y.; Lu, X. ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1. Nat. Cell. Biol., 2014, 16, 1092-1104.
46. Yang, A.D.; Fan, F.; Camp, E.R.; van Buren, G.; Liu, W.; Somcio, R.; Gray, M.J.; Cheng, H, Hoff, P.M.; Ellis, L.M. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res., 2006, 12, 4147- 4153.
47. Dallas, N.A.; Xia, L.; Fan, F.; Gray, M.J.; Gaur, P.; van Buren, G.; Samuel, S.; Kim, M.P.; Lim, S.J.; Ellis, L.M. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res., 2009, 69, 1951-1957
48. Marin-Aguilera, M.; Codony-Servat, J.; Reig, O.; Lozano, J.J.; Fernandez, P.L.; Pereira, M.V.; Jimenez, N.; Donovan, M.; Puig, P.; Mengual, L.; Bermudo, R.; Font, A.; Gallardo, E.; Ribal, M.J.; Alcaraz, A.; Gascon, P.; Mellado, B. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol. Cancer Ther., 2014, 13, 1270-1284
49. Ren, J.; Chen, Y.; Song, H.; Chen, L.; Wang, R. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J. Cell Biochem., 2013, 114, 1395- 1403
50. Rosano, L.; Cianfrocca, R.; Spinella, F.; Di Castro, V.; Nicotra, M.R.; Lucidi, A.; Ferrandina, G.; Natali, P.G.; Bagnato, A. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin. Cancer Res., 2011, 17, 2350-2360.
51. Camps, J.; Pitt, J.J.; Emons, G.; Hummon, A.B.; Case, C.M.; Grade, M.; Jones, T.L.; Nguyen, Q.T.; Ghadimi, B.M.; Beissbarth, T.; Difilippantonio, M.J.; Caplen, N.J.; Ried, T. Genetic amplification of the NOTCH modulator LNX2 upregulates the WNT/β-catenin pathway in colorectal cancer. Cancer Res., 2013, 73, 2003-2013
52. Hirsch, D.; Barker, N.; McNeil, N.; Hu, Y.; Camps, J.; McKinnon, K.; Clevers, H.; Ried, T.; Gaiser, T. LGR5 positivity defines stemlike cells in colorectal cancer. Carcinogenesis., 2014, 35, 849-858
53. Shiou, S.R.; Singh, A.B.; Moorthy, K.; Datta, P.K.; Washington, M.K.; Beauchamp, R.D.; Dhawan, P. Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells. Cancer Res., 2007, 67, 1571-1579.
54. Tian, X.; Du, H.; Fu, X.; Li, K.; Li, A.; Zhang, Y. Smad4 restoration leads to a suppression of Wnt/beta-catenin signaling activity and migration capacity in human colon carcinoma cells. Biochem. Biophys. Res. Commun., 2009, 380, 478-483.
55. Singh, A.B.; Sharma, A.; Smith, J.J.; Krishnan, M.; Chen, X.; Eschrich, S.; Washington, M.K.; Yeatman, T.J.; Beauchamp, R.D.; Dhawan, P. Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology, 2011, 141, 2140-2153.
56. Kwon, C.; Cheng, P.; King, I.N.; Andersen, P.; Shenje, L.; Nigam, V.; Srivastava, D. Notch post- translationally regulates β-catenin protein in stem and progenitor cells. Nat. Cell Biol., 2011, 13, 1244- 1251.
57. Sharma, S.V.; Lee, D.Y.; Li, B.; Quinlan, M.P.; Takahashi, F.; Maheswaran, S.; McDermott, U.; Azizian, N.; Zou, L.; Fischbach, M.A.; Wong, K.K.; Brandstetter, K.; Wittner, B.; Ramaswamy, S.; Classon, M.; Settleman, J.A chromatin-mediated reversible drugtolerant state in cancer cell subpopulations. Cell, 2010, 141, 69-80.
58. Chandarlapaty, S.; Sawai, A.; Scaltriti, M.; Rodrik-Outmezguine, V.; Grbovic-Huezo, O.; Serra, V.; Majumder, P.K.; Baselga, J.; Rosen, N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell, 2011, 19, 58-71.
59. Villanueva, J.; Vultur, A.; Lee, J.T.; Somasundaram, R.; Fukunaga- Kalabis, M.; Cipolla, A.K.; Wubbenhorst, B.; Xu, X.; Gimotty, P.A.; Kee, D.; Santiago-Walker, A.E.; Letrero, R.; D'Andrea, K.; Pushparajan, A.; Hayden, J.E.; Brown, K.D.; Laquerre, S.; McArthur, G.A.; Sosman, J.A.; Nathanson, K.L.; Herlyn, M. Acquired resistance to BRAF inhibitors medited by a RAF Kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 2010, 18, 683-695.
60. Lee, H.J.; Zhuang, G.; Cao, Y.; Du, P.; Kim, H.J.; Settleman, J. Drug resistance via feedback activation of Stat3 in oncogeneaddicted cancer cells. Cancer Cell, 2014, 26, 207-221
61. Corcoran, R.B.; Cheng, K.A.; Hata, A.N.; Faber, A.C.; Ebi, H.; Coffee, E.M. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell, 2013, 23, 121-128.
62. Sundvall, M.; Korhonen, A.; Vaparanta, K.; Anckar, J.; Halkilahti, K.; Salah, Z.; Aqeilan, R.I.; Palvimo, J.J.; Sistonen, L.; Elenius, K. Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein. J. Biol. Chem., 2012, 287, 23216-23226.
63. Aleksic, T.; Chitnis, M.M.; Perestenko, O.V.; Gao, S.; Thomas, P.H.; Turner, G.D.; Protheroe, A.S.; Howarth, M.; Macaulay, V.M. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res., 2010, 70, 6412-6419.
64. Sehat, B.; Tofigh, A.; Lin, Y.; Trocme, E.; Liljedahl, U.; Lagergren, J.; Larsson, O. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci. Signal, 2010, 3, 1-9.
65. Deng, H.; Lin, Y.; Badin, M.; Vasilcanu, D.; Stromberg, T.; Jernberg-Wiklund, H.; Sehat, B.; Larsson, O. Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9. Biochem. Biophys. Res. Commun., 2011, 404, 667-671
66. Warsito, D.; Sjostrom, S.; Andersson, S.; Larsson, O.; Sehat, B. Nuclear IGF1R is a transcriptional co-activator of LEF1/ TCF. EMBO Rep., 2012, 13, 244-250.
67. Cohn, A.L.; Tabernero, J.; Maurel, J.; Nowara, E.; Sastre, J.; Chuah, B.Y.; Kopp, M.V.; Sakaeva, D.D.; Mitchell, E.P.; Dubey, S.; Suzuki, S.; Hei, Y.J.; Galimi, F.; McCaffery, I.; Pan, Y.; Loberg, R.; Cottrell, S.; Choo, S.P. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann. Oncol., 2013, 24, 1777-1785
68. Van Cutsem, E.; Eng, C.; Nowara, E.; Swieboda-Sadlej, A.; Tebbutt, N.C.; Mitchell, E.; Davidenko, I.; Stephenson, J.; Elez, E.; Prenen, H.; Deng, H.; Tang, R.; McCaffery, I.; Oliner, K.S.; Chen, L.; Gansert, J.; Loh, E.; Smethurst, D.; Tabernero, J. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin. Cancer Res., 2014, 20, 4240- 4250
69. Friedl, P.; Alexander, S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell, 2011, 147, 992-1009.
70. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 2012, 366, 2455- 2465.
71. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; Spigel, D.R.; Antonia, S.J.; Horn, L.; Drake, C.G.; Pardoll, D.M.; Chen, L.; Sharfman, W.H.; Anders, R.A.; Taube, J.M.; McMiller, T.L.; Xu, H.; Korman, A.J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G.D.; Gupta, A.; Wigginton, J.M.; Sznol, M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med., 2012, 366, 2443-2454.
72. Taube, J.M.; Klein, A.; Brahmer, J.R.; Xu, H.; Pan, X.; Kim, J.H.; Chen, L.; Pardoll, D.M.; Topalian, S.L.; Anders, R.A.. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clin. Cancer Res., 2014, 20, 5064-5074
73. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; Zinzindohoue, F.; Bruneval, P.; Cugnenc, P.H.; rajanoski, Z.; Fridman, W.H.; Pages, F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 2006, 313, 1960-1964
74. Mlecnik, B.; Tosolini, M.; Kirilovsky, A.; Berger, A.; Bindea, G.; Meatchi, T.; Bruneval, P.; Trajanoski, Z.; Fridman, W.H.; Pages, F.; Galon, J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol., 2011, 29, 610-618
75. Droeser, R.A.; Hirt, C.; Viehl, C.T.; Frey, D.M.; Nebiker, C.; Huber, X.; Zlobec, I.; Eppenberger-Castori, S.; Tzankov, A.; Rosso, R.; Zuber, M.; Muraro, M.G.; Amicarella, F.; Cremonesi, E.; Heberer, M.; Iezzi, G.; Lugli, A.; Terracciano, L.; Sconocchia, G.; Oertli, D.; Spagnoli, G.C.; Tornillo, L. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur. J. Cancer, 2013, 49, 2233-2242.
76. Gatalica, Z.; Snyder, C.; Maney, T.; Ghazalpour, A.; Holterman, D.A.; Xiao, N.; Overberg, P.; Rose, I.; Basu, G.D.; Vranic, S.; Lynch, H.T.; Von Hoff, D.D.; Hamid, O. Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type. Cancer Epidemiol. Biomarkers. Prev., 2014, 12, 2965-2970.
77. Llosa, N.J.; Cruise, M.; Tam, A.; Wick, E.C.; Hechenbleikner, E.M.; Taube, J.M.; Blosser, L.; Fan, H.; Wang, H.; Luber, B.; Zhang, M.; Papadopoulos, N.; Kinzler, K.W.; Vogelstein, B.; Sears, C.L.; Anders, R.A.; Pardoll, D.M.; Housseau, F. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov., 2015, 5, 43-51.
78. Akbay, E.A.; Koyama, S.; Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov., 2013, 3, 1355-1363.
79. Xu, C.; Fillmore, C.M.; Koyama, S.; Wu, H.; Zhao, Y.; Chen, Z.; Herter-Sprie, G.S.; Akbay, E.A.; Tchaicha, J.H.; Altabef, A.; Reibel, J.B.; Walton, Z.; Ji, H.; Watanabe, H.; Janne, P.A.; Castrillon, D.H.; Rustgi, A.K.; Bass, A.J.; Freeman, G.J.; Padera, R.F.; Dranoff, G.; Hammerman, P.S.; Kim, C.F.; Wong, K.K. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell, 2014, 25, 590-2604.
80. Parsa, A.T.; Waldron, J.S.; Panner, A.; Crane, C.A.; Parney, I.F.; Barry, J.J.; Cachola, K.E.; Murray, J.C.; Tihan, T.; Jensen, M.C.; Mischel, P.S.; Stokoe, D.; Pieper, R.O. l.Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med., 2007, 13, 84-88.
81. Marzec, M.; Zhang, Q.; Goradia, A.; Raghunath, P.N.; Liu, X.; Paessler, M.; Wang, H.Y.; Wysocka, M.; Cheng, M.; Ruggeri, B.A.; Wasik, M.A. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl. Acad. Sci. USA., 2008, 105, 20852-20857.
82. Jiang, X.; Zhou, J.; Giobbie-Hurder, A.; Wargo, J.; Hodi, F.S. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin. Cancer Res., 2013, 19, 598-609.
83. Atefi, M.; Avramis, E.; Lassen, A.; Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res., 2014, 20, 3446-3457.
84. Wang, W.S.; Chen, P.M.; Wang, H.S.; Liang, W.Y.; Su, Y. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis, 2006, 27, 1113-1120.
85. Zeestraten, E.C.; Benard, A.; Reimers, M.S.; Schouten, P.C.; Liefers, G.J.; van de Velde, C.J.; Kuppen, P.J. The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry. Biomarkers. Cancer, 2013, 5, 13.
86. Maecker, H.L.; Koumenis, C.; Giaccia, A.J. p53 promotes selection for Fas-mediated apoptotic resistance. Cancer Res., 2000, 60, 4638- 4644.
87. Zalcenstein, A.; Stambolsky, P.; Weisz, L.; Muller, M.; Wallach, D.; Goncharov, T.M.; Krammer, P.H.; Rotter, V.; Oren, M. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene, 2003, 22, 5667-5676.
88. Strand, S.; Vollmer, P.; van den Abeelen, L.; Gottfried, D.; Alla, V.; Heid, H.; Kuball, J.; Theobald, M.; Galle, P.R.; Strand, D. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene, 2004, 23, 3732-3736.
89. Gallego, R.; Codony-Servat, J.; Garcia-Albeniz, X.; Carcereny, E.; Longaron, R.; Oliveras, A.; Tosca, M.; Auge, J.M.; Gascon, P.; Maurel, J. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. Endocr. Relat. Cancer, 2009, 16, 311-317.
90. Singh, S.; Srivastava, S.K.; Bhardwaj, A.; Owen, L.B.; Singh, A.P. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br. J. Cancer, 2010, 103, 1671-1679.
91. Feig, C.; Jones, J.O.; Kraman, M.; Wells, R.J.; Deonarine, A.; Chan, D.S.; Connell, C.M.; Roberts, E.W.; Zhao, Q.; Caballero, O.L.; Teichmann, S.A.; Janowitz, T.; Jodrell, D.I.; Tuveson, D.A.; Fearon, D.T. Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA., 2013, 110, 20212-20217.
92. Mace, T.A.; Ameen, Z.; Collins, A.; Wojcik, S.; Mair, M.; Young, G.S.; Fuchs, J.R.; Eubank, T.D.; Frankel, W.L.; Bekaii-Saab, T.; Bloomston, M.; Lesinski, G.B. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res., 2013, 73, 3007-3018.
93. Mitchem, J.B.; Brennan, D.J.; Knolhoff, B.L.; Belt, B.A.; Zhu, Y.; Sanford, D.E.; Belaygorod, L.; Carpenter, D.; Collins, L.; Piwnica- Worms. D.; Hewitt. S.; Udupi, G.M.; Gallagher, W.M.; Wegner, C.; West, B.L.; Wang-Gillam, A.; Goedegebuure, P.; Linehan, D.C.; DeNardo, D.G. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res., 2013, 73, 1128-1141.
94. Hu, X.; Bardhan, K.; Paschall, A.V.; Yang, D.; Waller, J.L.; Park, M.A.; Nayak-Kapoor, A.; Samuel, T.A.; Abrams, S.I.; Liu, K. Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer. J. Biol. Chem., 2013, 288, 19103- 19115.
95. Lesina, M.; Kurkowski, M.U.; Ludes, K.; Rose-John, S.; Treiber, M.; Kloppel, G.; Yoshimura, A.; Reindl, W.; Sipos, B.; Akira, S.; Schmid, R.M.; Algul, H. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell, 2011, 19, 456-469.
96. Pelisch, F.; Khauv, D.; Risso, G.; Stallings-Mann, M.; Blaustein, M.; Quadrana, L.; Radisky, D.C.; Srebrow, A. Involvement of hnRNP A1 in the matrix metalloprotease-3-dependent regulation of Rac1 pre-mRNA splicing. J. Cell Biochem., 2012, 113, 2319-2329.
97. Nelson, C.M.; Khauv, D.; Bissell, M.J.; Radisky, D.C. Change in cell shape is required for matrix metalloproteinase-induced epithelialmesenchymal transition of mammary epithelial cells. J. Cell Biochem., 2008, 105, 25-33.
98. Lee, K.; Chen, Q.K.; Lui, C.; Cichon, M.A.; Radisky, D.C.; Nelson, C.M. Matrix compliance regulates Rac1b localization, NADPH oxidase assembly, and epithelial-mesenchymal transition. Mol. Biol. Cell., 2012, 23, 4097-4108.
99. Mehner, C.; Miller, E.; Khauv, D.; Nassar, A.; Oberg, A.L.; Bamlet, W.R.; Zhang, L.; Waldmann, J.; Radisky, E.S.; Crawford, H.C.; Radisky, D.C. Tumor Cell-Derived MMP3 Orchestrates Rac1b and Tissue Alterations That Promote Pancreatic Adenocarcinoma. Mol. Cancer Res., 2014, 12, 1430-1439
100. Wu, X.; Zhang, H.; Xing, Q.; Cui, J.; Li, J.; Li, Y.; Tan, Y.; Wang, S. PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br. J. Cancer, 2014, 11, 1391-1399
101. Listopad, J.J.; Kammertoens, T.; Anders, K.; Silkenstedt, B.; Willimsky, G.; Schmidt, K.; Kuehl, A.A.; Loddenkemper, C.; Blankenstein, T. Fas expression by tumor stroma is required for cancer eradication. Proc. Natl. Acad. Sci. USA., 2013, 110, 2276- 2281
102. Tanaka, M.; Itai, T.; Adachi, M.; Nagata, S. Downregulation of Fas ligand by shedding. Nat. Med., 1998, 4, 31-36
103. Maurel, J.; Nadal, C.; Garcia-Albeniz, X.; Gallego, R.; Carcereny, E.; Almendro, V.; Marmol, M.; Gallardo, E.; Maria Auge, J.; Longaron, R.; Martinez-Fernandez, A.; Molina, R.; Castells, A.; Gascon, P. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int. J. Cancer, 2007, 121, 1066-1071
104. Vargo-Gogola, T.; Crawford, H.C.; Fingleton, B.; Matrisian, L.M. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch. Biochem. Biophys., 2002, 408, 155-161
105. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature, 2012, 487, 330-337.
106. Venderbosch, S.; Nagtegaal, I.D.; Maughan, T.S.; Smith, C.G.; Cheadle, J.P.; Fisher, D.; Kaplan, R.; Quirke, P.; Seymour, M.T.; Richman, S.D.; Meijer, G.A.; Ylstra, B.; Heideman, D.A.; de Haan, A.F.; Punt, C.J.; Koopman, M. Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clin. Cancer Res., 2014, 20, 5322-5330.
107. Haan J.C.; Labotsm, M.; Rauschm, C.; Koopman, M.; Tol, J.; Mekenkamp, L.J.; van de Wiel, M.A.; Israeli, D.; van Essen, H.F.; van Grieken, N.C.; Voorham, Q.J.; Bosch, L.J.; Qu, X.; Kabbarah, O.; Verheul, H.M.; Nagtegaal, I.D.; Punt, C.J.; Ylstra, B.; Meijer, G.A. Genomic landscape of metastatic colorectal cancer. Nat. Commun., 2014, 5, 5457
108. Sadanandam, A.; Lyssiotis, C.A.; Homicsko, K.; Collisson, E.A.; Gibb, W.J.; Wullschleger, S.; Ostos, L.C.; Lannon, W.A.; Grotzinger, C.; Del Rio, M.; Lhermitte, B.; Olshen, A.B.; Wiedenmann, B.; Cantley, L.C.; Gray, J.W.; Hanahan, D. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med., 2013, 19, 619-625.
109. De Sousa Melo, F.; Wang, X.; Jansen, M.; Fessler, E.; Trinh, A.; de Rooij, L.P.; de Jong, J.H.; de Boer, O.J.; van Leersum, R.; Bijlsma, M.F.; Rodermond, H.; van der Heijden, M.; van Noesel, C.J.; Tuynman, J.B.; Dekker, E.; Markowetz, F.; Medema, J.P.; Vermeulen, L. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med., 2013, 19, 614-618.
110. Kohne, C.H.; Cunningham, D.; Di Costanzo, F.; Glimelius, B.; Blijham, G.; Aranda, E.; Scheithauer, W.; Rougier, P.; Palmer, M.; Wils, J.; Baron, B.; Pignatti, F.; Schoffski, P.; Micheel, S.; Hecker, H. Clinical determinants of survival in patients with 5-flurouracilbased treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann. Oncol., 2002, 13, 308- 317.
111. Chibaudel, B.; Bonnetain, F.; Tournigand, C.; Bengrine-Lefevre, L.; Teixeira, L.; Artru, P.; Desrame, J.; Larsen, A.K.; Andre, T.; Louvet, C.; de Gramont, A. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist., 2011, 16, 1228-1238.
112. Saltz, L.B.; Clarke, S.; Diaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T.S.; Rivera, F.; Couture, F.; Sirzen, F.; Cassidy, J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol., 2008, 26, 2013-2019.
113. Loupakis, F.; Cremolini, C.; Masi, G.; Lonardi, S.; Zagonel, V.; Salvatore, L.; Cortesi, E.; Tomasello, G.; Ronzoni, M.; Spadi, R.; Zaniboni, A.; Tonini, G.; Buonadonna, A.; Amoroso, D.; Chiara, S.; Carlomagno, C.; Boni, C.; Allegrini, G.; Boni, L.; Falcone, A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N. Engl. J. Med., 2014, 371, 1609-1618
114. Giantonio, B.J.; Catalano, P.J.; Meropol, N.J.; O'Dwyer, P.J.; Mitchell, E.P.; Alberts, S.R.; Schwartz, M.A.; Benson, A. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol., 2007, 25, 1539-1544.
115. Van Cutsem, E.; Tabernero, J.; Lakomy, R.; Prenen, H.; Prausova, J.; Macarulla, T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, P.; likoff, J.; Tellier, A.; Castan, R.; Allegra, C. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. J. Clin. Oncol., 2012, 30, 3499-3506.
116. Bennouna, J.; Sastre, J.; Arnold, D.; Osterlund, P.; Greil, R.; Van Cutsem, E.; von Moos, R.; Vieitez, J.M.; Bouche, O.; Borg, C.; Steffens, C.C.; Alonso-Orduna, V.; Schlichting, C.; Reyes-Rivera, I.; Bendahmane, B.; Andre, T.; Kubicka, S. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol., 2013, 14, 29-37.
117. Tabernero, J.; Yoshino, T.; Cohn, A.L.; Obermannova, R.; Bodoky, G.; Garcia-Carbonero, R.; Ciuleanu, T.E.; Portnoy, D.C.; Van Cutsem, E.; Grothey, A.; Prausova, J.; Garcia-Alfonso, P.; Yamazaki, K.; Clingan, P.R.; Lonardi, S,; Kim, T.W.; Simms, L.; Chang, S.C.; Nasroulah, F. RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol., 2015, 16, 499-508
118. Ihle, N.T.; Byers, L.A.; Kim, E.S.; Saintigny, P.; Lee, J.J.; Blumenschein, G.R.; Tsao, A.; Liu, S.; Larsen, J.E.; Wang, J.; Diao, L.; Coombes, K.R.; Chen, L.; Zhang, S.; Abdelmelek, M.F.; Tang, X.; Papadimitrakopoulou, V.; Minna, J.D.; Lippman, S.M.; Hong, W.K.; Herbst, R.S.; Wistuba, II.; Heymach, J.V.; Powis, G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl. Cancer Inst., 2012, 104, 228-239
119. Wee, S.; Jagani, Z.; Xiang, K.X.; Loo, A.; Dorsch, M.; Yao, Y.M.; Sellers, W.R.; Lengauer, C.; Stegmeier, F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res., 2009, 69, 4286-4293
120. Yeh, J.J.; Routh, E.D.; Rubinas, T.; Peacock, J.; Martin, T.D.; Shen, X.J.; Sandler, R.S.; Kim, H.J.; Keku, T.O.; Der, C.J. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol. Cancer Ther., 2009, 8, 834-843
121. Ebi, H.; Corcoran, R.B.; Singh, A.; Chen, Z.; Song, Y.; Lifshits, E.; Ryan, D.P.; Meyerhardt, J.A.; Benes, C.; Settleman, J.; Wong, K.K.; Cantley, L.C.; Engelman, J.A. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J. Clin. Invest., 2011, 121, 4311-4321.
122. Migliardi, G.; Sassi, F.; Torti, D.; Galimi, F.; Zanella, E.R.; Buscarino, M.; Ribero, D.; Muratore, A.; Massucco, P.; Pisacane, A.; Risio, M.; Capussotti, L.; Marsoni, S.; Di Nicolantonio, F.; Bardelli, A.; Comoglio, P.M.; Trusolino, L.; Bertotti, A. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RASmutant colorectal carcinomas. Clin. Cancer Res., 2012, 18, 2515- 2525
123. Faber, A.C.; Coffee, E.M.; Costa, C.; Dastur, A.; Ebi, H.; Hata, A.N.; Yeo, A.T.; Edelman, E.J.; Song, Y.; Tam, A.T.; Boisvert, J.L.; Milano, R.J.; Roper, J.; Kodack, D.P.; Jain, R.K.; Corcoran, R.B.; Rivera, M.N.; Ramaswamy, S.; Hung, K.E.; Benes, C.H.; Engelman, J.A. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov., 2014, 4, 42-52
124. Fischer, M.; Yen, W.C.; Kapoun, A.M.; Wang, M.; O'Young, G.; Lewicki, J.; Gurney, A.; Hoey, T. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res., 2011, 71, 1520-1525
125. Tenbaum, S.P.; Ordonez-Moran, P.; Puig, I.; Chicote, I.; Arques, O.; Landolfi, S.; Fernandez, Y.; Herance, J.R.; Gispert, J.D.; Mendizabal, L.; Aguilar, S.; Ramon, Y.; Cajal, S.; Schwartz, S.; Vivancos, A.; Espin, E.; Rojas, S.; Baselga, J.; Tabernero, J.; Munoz, A.; Palmer, H.G. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat. Med., 2012, 18, 892-901
126. Martin, T.D.; Samuel, J.C.; Routh, E.D.; Der, C.J.; Yeh, J.J. Activation and involvement of Ral GTPases in colorectal cancer. Cancer Res., 2011, 71, 206-215.
127. Tol, J.; Nagtegaal, I.D.; Punt, C.J. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med., 2009, 361, 98-99
128. Di Nicolantonio, F.; Martini, M.; Molinari, F.; Sartore-Bianchi, A.; Arena, S.; Saletti, P.; De Dosso, S.; Mazzucchelli, L.; Frattini, M.; Siena, S.; Bardelli, A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol., 2008, 26, 5705-5712.
129. Ince, W.L.; Jubb, A.M.; Holden, S.N.; Holmgren, E.B.; Tobin, P.; Sridhar, M.; Hurwitz, H.I.; Kabbinavar, F.; Novotny, W.F.; Hillan, K.J.; Koeppen, H. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Natl. Cancer Inst., 2005, 97, 981-989
130. Price, T.J.; Hardingham, J.E.; Lee, C.K.; Weickhardt, A.; Townsend, A.R.; Wrin, J.W.; Chua, A.; Shivasami, A.; Cummins, M.M.; Murone, C.; Tebbutt, N.C. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J. Clin. Oncol., 2011, 29, 2675-2682
131. Pratilas, C.A.; Taylor, B.S.; Ye, Q.; Viale, A.; Sander, C.; Solit, D.B.; Rosen, N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA., 2009, 106, 4519-4524
132. Wickenden, J.A.; Jin, H.; Johnson, M.; Gillings, A.S.; Newson, C.; Austin, M.; Chell, S.D.; Balmanno, K.; Pritchard, C.A.; Cook, S.J. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene., 2008, 27, 7150-7161.
133. Yang, H.; Higgins, B.; Kolinsky, K.; Packman, K.; Bradley, W.D.; Lee, R.J.; Schostack, K.; Simcox, M.E.; Kopetz, S.; Heimbrook, D.; Lestini, B.; Bollag, G.; Su, F. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res., 2012, 72, 779-89
134. Kopetz, J.; Desai, E.; Chan, J.R. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol., 2010, 28.
135. Matos, P.; Oliveira, C.; Velho, S.; Goncalves, V.; da Costa, L.T.; Moyer, M.P.; Seruca, R.; Jordan, P. B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. Gastroenterology, 2008, 135, 899-906.
136. Corcoran, R.B.; Ebi, H.; Turke, A.B.; Coffee, E.M.; Nishino, M.; Cogdill, A.; Brown, R.D.; Della Pelle, P.; Dias-Santagata, D.; Hung, K.E.; Flaherty, K.T.; Piris, A.; Wargo, J.A.; Settleman, J.; Mino-Kenudson, M.; Engelman, J.A. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov., 2012, 2, 227-35
137. Prahallad, A.; Sun, C.; Huang, S.; Di Nicolantonio, F.; Salazar, R.; Zecchin, D.; Beijersbergen, R.L.; Bardelli, A.; Bernards, R. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483, 100-103
138. Rad, R.; Cadinanos, J.; Rad, L.; Varela, I.; Strong, A.; Kriegl, L.; Constantino-Casas, F.; Eser, S.; Hieber, M.; Seidler, B.; Price, S.; Fraga, M.F.; Calvanese, V.; Hoffman, G.; Ponstingl, H.; Schneider, G.; Yusa, K.; Grove, C.; Schmid, R.M.; Wang, W.; Vassiliou, G.; Kirchner, T.; McDermott, U.; Liu, P.; Saur, D.; Bradley, A. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell, 2013, 24, 15-29.
139. Coffee, E.M.; Faber, A.C.; Roper, J.; Sinnamon, M.J.; Goel, G.; Keung, L.; Wang, W.V.; Vecchione, L.; de Vriendt, V.; Weinstein, B.J.; Bronson, R.T.; Tejpar, S.; Xavier, R.J.; Engelman, J.A.; Martin, E.S.; Hung, K.E. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin. Cancer Res., 2013, 19, 2688-2698
140. Mao, M.; Tian, F.; Mariadason, J.M.; Tsao, C.C.; Lemos, R.; Dayyani, F.; Gopal, Y.N.; Jiang, Z.Q.; Wistuba, I.I.; Tang, X.M.; Bornman, W.G.; Bollag, G.; Mills, G.B.; Powis, G.; Desai, J.; Gallick, G.E.; Davies, M.A.; Kopetz, S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin. Cancer Res., 2013, 19, 657-667
141. Seruca, R.; Velho, S.; Oliveira, C.; Leite, M.; Matos, P.; Jordan, P. Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors. Expert Rev. Gastroenterol. Hepatol., 2009, 3, 5- 9.
142. Ahronian, L.G.; Sennott, E.M.; Van Allen, E.M.; Wagle, N.; Kwak, E.L.; Faris, J.E.; Godfrey, J.T.; Nishimura, K.; Lynch, K.D.; Mermel, C.H.; Lockerman, E.L.; Kalsy, A.; Gurski, J.; Bahl, S.; Anderka, K.; Green, L.M.; Lennon, N.J.; Huynh, T.G.; Mino Kenudson, M.; Getz, G.; Dias-Santagata, D.; Iafrate, A.J.; Engelman, J.A.; Garraway, L.A.; Corcoran, R.B. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov., 2015, 5, 358-367
143. Corcoran, R.B.; Atreya, C.E.; Falchook, G.S. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametenib (T) in BRAF V600 mutant colorectal cancer (CRC): updated efficacy and biomarker analysis. J. Clin. Oncol., 2014, 32, 5.
144. Bendell, J.C.; Atreya, C.E.; Andre, T. Efficacy and tolerability in an open-label phase I-II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafebnib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J. Clin. Oncol., 2014, 32, 5.
145. Geel, R.V.; Ellez, E.; Bendell, J.C. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the alpha specific PI3K inhibitor BYL179 in patients with advanced BRAF mutant colorectal cancer. J. Clin. Oncol., 2014, 32, 5.
146. Alonso-Espinaco, V.; Cuatrecasas, M.; Alonso, V.; Escudero, P.; Marmol, M.; Horndler, C.; Ortego, J.; Gallego, R.; Codony-Servat, J.; Garcia-Albeniz, X.; Jares, P.; Castells, A.; Lozano, J.J.; Rosell, R.; Maurel, J. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer (mCRC) patients treated with first-line FOLFOX/XELOX chemotherapy. Eur. J. Cancer, 2014, 50, 1973-1981.
147. Misale, S.; Yaeger, R.; Hobor, S.; Scala, E.; Janakiraman, M.; Liska, D.; Valtorta, E.; Schiavo, R.; Buscarino, M.; Siravegna, G.; Bencardino, K.; Cercek, A.; Chen, C.T.; Veronese, S.; Zanon, C.; Sartore-Bianchi, A.; Gambacorta, M.; Gallicchio, M.; Vakiani, E.; Boscaro, V.; Medico, E.; Weiser, M.; Siena, S.; Di Nicolantonio, F.; Solit, D.; Bardelli, A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 2012, 486, 532-536.
148. Diaz, L.; Williams, R.T.; Wu, J.; Kinde, I.; Hecht, J.R.; Berlin, J.; Allen, B.; Bozic, I.; Reiter, J.G.; Nowak, M.A.; Kinzler, K.W.; Oliner, K.S.; Vogelstein, B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature, 2012, 486, 537-540.
149. Spindler, K.L.; Pallisgaard, N.; Andersen, R.F.; Jakobsen, A. Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int. J. Cancer, 2014, 135, 2215-2222.
150. Barcelo, C.; Paco, N.; Morell, M.; Alvarez-Moya, B.; Bota- Rabassedas, N.; Jaumot, M.; Vilardell, F.; Capella, G.; Agell, N. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth. Cancer Res., 2014, 74, 1190-1199
151. Mohan, S.; Heitzer, E.; Ulz, P.; Lafer, I.; Lax, S.; Auer, M.; Pichler, M.; Gerger, A.; Eisner, F.; Hoefler, G.; Bauernhofer, T.; Geigl, J.B.; Speicher, M.R. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet., 2014, 10, 1004271.
152. Liska, D.; Chen, C.T.; Bachleitner-Hofmann, T.; Christensen, J.G.; Weiser, M.R. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin. Cancer Res., 2011, 17, 472- 482.
153. Bardelli, A.; Corso, S.; Bertotti, A.; Hobor, S.; Valtorta, E.; Siravegna, G.; Sartore-Bianchi, A.; Scala, E.; Cassingena, A.; Zecchin, D.; Apicella, M.; Migliardi, G.; Galimi, F.; Lauricella, C.; Zanon, C.; Perera, T.; Veronese, S.; Corti, G.; Amatu, A.; Gambacorta, M.; Diaz, L.A.; Sausen, M.; Velculescu, V.E.; Comoglio, P.; Trusolino, L.; Di Nicolantonio, F.; Giordano, S.; Siena, S. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov., 2013, 3, 658-673
154. Troiani, T.; Martinelli, E.; Napolitano, S.; Vitagliano, D.; Ciuffreda, L.P.; Costantino, S.; Morgillo, F.; Capasso, A.; Sforza, V.; Nappi, A.; De Palma, R.; D'Aiuto, E.; Berrino, L.; Bianco, R.; Ciardiello, F. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFRMET interaction and activation of MET signaling in colon cancer cells. Clin. Cancer Res., 2013, 19, 6751-6765
155. Luraghi, P.; Reato, G.; Cipriano, E.; Sassi, F.; Orzan, F.; Bigatto, V.; De Bacco, F.; Menietti, E.; Han, M.; Rideout, W.; Perera, T.; Bertotti, A.; Trusolino, L.; Comoglio, P.M.; Boccaccio, C. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res., 2014, 74, 1857-1869.
156. Li, C.; Iida, M.; Dunn, E.F.; Ghia, A.J.; Wheeler, D.L. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene, 2009, 28, 3801-3813.
157. Oliveras-Ferraros, C.; Vazquez-Martin, A.; Cufi, S.; Queralt, B.; Baez, L.; Guardeno, R.; Hernandez-Yague, X.; Martin-Castillo, B.; Brunet, J.; Menendez, J.A. Oliveras Stem cell property epithelialto- mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells. J. Cell Biochem., 2011, 112, 10-29
158. Ocana, A.; Tannock, I.F. When are "positive" clinical trials in oncology truly positive? J. Natl. Cancer Inst., 2011, 103, 16-20.
159. Ellis, L.M.; Bernstein, D.S.; Voest, E.E.; Berlin, J.D.; Sargent, D.; Cortazar, P. American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J. Clin. Oncol., 2014, 32, 1277-1280.
160. Mandrekar, S.J.; Sargent, D.J. Clinical trials designs for predictive biomarker validation: Theoretical considerations and practical challenges. J. Clin. Oncol., 2009, 27, 4027-4034.